KARYOPHARM THERAPEUTICS INC.Karyopharm Therapeutics Inc. • August 31st, 2020 • Pharmaceutical preparations • Massachusetts
Subject to your execution below, this letter hereby amends the offer letter, dated March 3, 2014, as amended and restated on January 23, 2015 and September 18, 2015, between you and Karyopharm Therapeutics Inc. (the “Company”), and provides for the following terms of employment. For the avoidance of doubt, nothing herein supersedes the Non-Disclosure and Inventions Assignment Agreement you previously executed with the Company, which remains in effect, unaltered, in all respects.
August 28, 2020 Michael Mason Dear Mike:Karyopharm Therapeutics Inc. • August 31st, 2020 • Pharmaceutical preparations
You and Karyopharm Therapeutics Inc. (the “Company”) are parties to a letter agreement dated February 1, 2019 related to your employment as the Senior Vice President, Chief Financial Officer and Treasurer of the Company (the “Letter Agreement”). This letter is to inform you that the Compensation Committee of the Board of Directors of the Company approved certain enhanced severance benefits for you, as described below, in addition to the benefits you may be entitled to under the Letter Agreement. Except as specifically set forth below, the Letter Agreement remains in full force and effect, and no provisions thereof are amended except as set forth below. Capitalized terms used but not defined herein shall have the meaning set forth in the Letter Agreement.
